Washington is currently home to 1691 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Seattle, Spokane, Tacoma and Bellevue. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Liquid Biopsy in Ewing Sarcoma and Osteosarcoma As a Prognostic and Response Diagnostic: LEOPARD
NCT06068075
Recruiting
This is a prospective multicenter biomarker study evaluating the prognostic impact of ctDNA detection at diagnosis in patients with Ewing sarcoma or osteosarcoma.
Gender:
ALL
Ages:
Between 12 months and 50 years
Trial Updated:
01/17/2025
Locations: Seattle Children's Hospital, Seattle, Washington
Conditions: Ewing Sarcoma, Ewing Sarcoma of Bone, Ewing Sarcoma of Soft Tissue, Peripheral Primitive Neuroectodermal Tumor, Peripheral Primitive Neuroectodermal Tumor of Bone, Peripheral Primitive Neuroectodermal Tumor of Soft Tissue, High-grade Osteosarcoma
Register for Updates
NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
NCT05359211
Recruiting
This phase Ib trial studies the effects of NKTR-255 in combination with chimeric antigen (CAR)-T cell therapy and to see how well they work in treating patients with large B-cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory). NKTR-255 is an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. T cells are infection fighting blood cells that can kill tumor cells. Lisocabtagene maraleucel is a CAR-T cell... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/17/2025
Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington
Conditions: Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory Grade 3b Follicular Lymphoma, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma, Recurrent Primary Mediastinal Large B-Cell Lymphoma, Refractory Primary Mediastinal Large B-Cell Lymphoma
Register for Updates
Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study
NCT05104983
Recruiting
This trial is a Phase II randomized, double-blind, placebo controlled multi-site study to evaluate the safety and efficacy of early sirolimus to prevent or delay seizure onset in TSC infants. This study is supported by research funding from the Office of Orphan Products Division (OOPD) of the US Food and Drug Administration (FDA).
Gender:
ALL
Ages:
Between 1 day and 6 months
Trial Updated:
01/17/2025
Locations: Seattle Children's Hospital, Seattle, Washington
Conditions: Tuberous Sclerosis Complex, Epilepsy
Register for Updates
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma
NCT04442022
Recruiting
The purpose of this Phase 2/3 study is to evaluate efficacy and safety of the combination of selinexor and R-GDP (SR-GDP) in patients with RR DLBCL who are not intended to receive hematopoetic stem cell transplantation (HSCT) or chimeric antigen receptor T cell (CAR-T) therapy. This study consists of 3 arms each in Phase 2 and 3. Phase 2 portion of the study will assess the two doses of selinexor (40 milligram \[mg\] or 60 mg) in combination with R-GDP, for up to 6 cycles (21-day per cycle), fol... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/17/2025
Locations: Providence Regional Cancer Partnership, Everett, Washington
Conditions: Relapsed/Refractory Diffuse Large B-cell Lymphoma
Register for Updates
High-intensity Interval Circuit Training in People With Parkinson Disease
NCT06576817
Recruiting
The goal of the study is to compare different types of high intensity circuit exercises over an 8-class training series in people with Parkinson disease. The main question it aims to answer is: -Does including arm and hand exercises with leg exercises improve reaction time, balance, functional measures, gait speed and quality of life? This group will be compared to a group that only does leg exercises. Participants will be asked to participate in 8 high intensity circuit exercise classes.
Gender:
ALL
Ages:
All
Trial Updated:
01/16/2025
Locations: Pacific Northwest University of Health Sciences, Yakima, Washington
Conditions: Parkinson Disease
Register for Updates
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
NCT06346067
Recruiting
Stage 1: To select the optimal dose of naporafenib + trametinib to be studied in Stage 2. Stage 2: To compare progression free survival (PFS) and overall survival (OS) for patients with NRAS-mutant (NRASm) melanoma who are randomized to receive the combination of naporafenib + trametinib to that of patients who are randomized to physician's choice of therapy (dacarbazine, temozolomide, or trametinib monotherapy).
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
01/16/2025
Locations: Fred Hutchinson Cancer Center, Seattle, Washington
Conditions: Advanced or Metastatic NRAS-mutant Melanoma
Register for Updates
A Phase 1 Study of ZL-1218 in Subjects With Advanced Solid Tumors
NCT05859464
Recruiting
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of ZL-1218 as a single agent and as combination therapy in subjects with advanced solid tumor malignancies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/16/2025
Locations: Zai Lab Site 2003, Spokane, Washington
Conditions: Malignant Solid Tumor
Register for Updates
A Prosthetic Foot Test-Drive Strategy for Improving Stability in Veterans With Leg Amputations
NCT05473065
Recruiting
Objective/Hypotheses and Specific Aims: The first aim of this proposal is to determine the effects of commercial prosthetic feet of varying stiffness on stability and falls-related outcomes in Veterans with TTA. The second aim is to determine whether a PFE can be used to predict stability and balance-confidence outcomes with corresponding commercial prosthetic feet. The third and final aim is to determine whether a brief trial of commercial prosthetic feet can predict longer-term stability and b... Read More
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
01/16/2025
Locations: VA Puget Sound Health Care System, Seattle, Washington
Conditions: Amputation
Register for Updates
ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)
NCT04829604
Recruiting
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients who were previously treated with T-DXd
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/16/2025
Locations: Research Site, Tacoma, Washington
Conditions: HER2 Positive Metastatic Breast Cancer
Register for Updates
Trial of 225Ac-DOTATATE (RYZ101) in Subjects with ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
NCT06590857
Recruiting
Phase 1b/2 open-label trial of 225Ac-DOTATATE (RYZ101) in subjects with ER+, HER2-negative unresectable or metastatic breast cancer expressing SSTRs.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/15/2025
Locations: Research Facility, Seattle, Washington
Conditions: Metastatic Breast Cancer, HER2-negative Breast Cancer, ER+ Breast Cancer, Advanced Breast Cancer
Register for Updates
The HistoSonics Edison™ System for Treatment of Primary Solid Renal Tumors Using Histotripsy (#HOPE4KIDNEY)
NCT05820087
Recruiting
The purpose of this trial is to evaluate the effectiveness and safety of the HistoSonics Edison System for the destruction of kidney tissue by treating primary solid renal tumors.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
01/15/2025
Locations: Swedish Medical Center, Seattle, Washington
Conditions: Renal Cancer, Tumor, Solid, Kidney Cancer, Tumor, Tumor, Benign
Register for Updates
Growth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD)
NCT04867317
Recruiting
The purpose of this study is to determine whether growth hormone replacement therapy (GHRT) is effective versus placebo in the improvement of Quality of Life in patients with adult growth hormone deficiency (AGHD) and mild traumatic brain injury (mTBI).
Gender:
ALL
Ages:
Between 21 years and 55 years
Trial Updated:
01/15/2025
Locations: VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle, Washington
Conditions: Adult Growth Hormone Deficiency, Mild Traumatic Brain Injury
Register for Updates